Get the Stockscreener App
16.80
5.51%
-0.98
Pre-market:
17.64
0.84
+5.00%
Neurogene Inc stock is traded at $16.80, with a volume of 146.45K.
It is down -5.51% in the last 24 hours and down -10.50% over the past month.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
See More
Previous Close:
$17.78
Open:
$17.85
24h Volume:
146.45K
Relative Volume:
0.63
Market Cap:
$249.56M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.30%
1M Performance:
-10.50%
6M Performance:
-59.95%
1Y Performance:
-53.41%
1-Day Range:
$16.36
$17.89
1-Week Range:
$16.36
$18.62
52-Week Range:
$14.42
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
16.80 | 249.56M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Rhumbline Advisers Buys 1,326 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401 - Seeking Alpha
Neurogene (NASDAQ:NGNE) Shares Down 8.4% – Here’s Why - Defense World
Neoleukin Therapeutics, Inc. Announces Reduction in the Workforce -March 08, 2023 at 05:00 pm EST - Marketscreener.com
Neurogene to Participate in Upcoming Conferences - Business Wire
Can These 3 Healthcare Conferences Reveal Neurogene's Next Big Move? - StockTitan
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - Yahoo Canada Finance
Neurogene (NGNE) to Release Quarterly Earnings on Monday - Defense World
Neurogene (NGNE) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neurogene Inc (NGNE) Shares Decline Despite Market Challenges - The News Heater
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - accessnewswire.com
Should You Expect Neurogene Inc (NASDAQ:NGNE) To Recover From Its 38.11% Gain From Highs? - Marketing Sentinel
Get in on Neurogene Inc’s (NGNE) buy-in window today! - SETE News
Neurogene Inc [NASDAQ: NGNE] Sees Increase in Stock Value - Knox Daily
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Neurogene Inc (NGNE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - Victoria Advocate
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Shareholders that Lost Money on Neurogene Inc. (NGNE) Should Contact Levi & Korsinsky About Securities Fraud InvestigationNGNE - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Barclays PLC Purchases 11,316 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Progress in Rett Syndrome Program - TipRanks
Jane Street Group LLC Invests $324,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives $60.83 Average PT from Analysts - MarketBeat
7,050 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Franklin Resources Inc. - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Sells 1,463 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Acquires 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Buys 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Charles Schwab Investment Management Inc. Buys 741 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
MetLife Investment Management LLC Invests $254,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Neurogene Inc Stock (NGNE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Nov 22 '24 |
Buy |
20.48 |
24,000 |
491,400 |
76,844 |
| McMinn Rachel | Chief Executive Officer |
Nov 22 '24 |
Buy |
20.40 |
47,500 |
969,000 |
1,297,859 |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):